BENDAMUSTINE‐RITUXIMAB (BR) VERSUS R‐CHOP AS UPFRONT THERAPY FOR INDOLENT B‐CELL LYMPHOMAS: A COMPARATIVE, POPULATION‐BASED ANALYSIS. (June 2017)